\
&
Contact us
This was 3 years ago
LocationOnline
ProgrammesOn July 7th 2022, NCP Flanders organises an info session on security-related topics within the European Defence Fund, Horizon Europe (Civil Security for Society) and Digital Europe (Cybersecurity).
The session aims to provide an overview on funding opportunities for researchers, companies and practitioners.
Calls for the European Defence Fund are expected to be published by June 9th 2022 and calls for projects on Civil Security for Society under Horizon Europe are expected to open on June 30th 2022. The next cybersecurity calls under Digital Europe are foreseen to open at the end of September 2022.
Preliminary agenda:
11.00 -11.05 Introduction – Mark Antonissen, NCP Flanders
11.05-11.30 European Defence Fund – Mark Antonissen, NCP Flanders
Presentation and Q&A
11.30-12.00 Horizon Europe: Civil Security in Society & Digital Europe: Cybersecurity -
Marie Timmermann, NCP Flanders
Presentation and Q&A
12.00-12.10 Development of work programmes -
Paris Van Paesschen, Department of Economics, Science & Innovation (Departement EWI)
12.10-12.30 Q&A
The info session will take place online.
Language: The event will be held in English.
Participation to this webinar is free, but registration via this link is mandatory and open until 1 July. You have the possibility to write any question you might have at this stage in the registration form. Please take this opportunity, as all the questions raised beforehand will be addressed in the relevant presentations.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.